相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fractalkine: A Survivor's Guide Chemokines as Antiapoptotic Mediators
Gemma E. White et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer
Julia Y. S. Tsang et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
D. H. Morrison et al.
BRITISH JOURNAL OF CANCER (2012)
CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling
A. Dubrovska et al.
BRITISH JOURNAL OF CANCER (2012)
High Expression of CX3CL1/CX3CR1 Axis Predicts a Poor Prognosis of Pancreatic Ductal Adenocarcinoma
Xianhui Xu et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2012)
CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function
Anna Corcione et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma
Min Ho Park et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
αB-crystallin, a small heat shock protein, modulates NF-κB activity in a phosphorylation-dependent manner and protects muscle myoblasts from TNF-α induced cytotoxicity
Amit S. Adhikari et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Identification of the Chemokine CX3CL1 as a New Regulator of Malignant Cell Proliferation in Epithelial Ovarian Cancer
Francoise Gaudin et al.
PLOS ONE (2011)
The chemokine receptor CX(3)CR1 is directly involved in the arrest of breast cancer cells to the skeleton
Whitney L. Jamieson-Gladney et al.
BREAST CANCER RESEARCH (2011)
Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1
Marco Erreni et al.
EUROPEAN JOURNAL OF CANCER (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1
Giuseppe Sciume et al.
NEURO-ONCOLOGY (2010)
Constitutive Endocytosis of the Chemokine CX3CL1 Prevents Its Degradation by Cell Surface Metalloproteases
Yi-Wei Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Increased expression of Fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma
Miki Hyakudomi et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma
Federica Marchesi et al.
CANCER RESEARCH (2008)
Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-κB
Pankaj K. Bhavsar et al.
FASEB JOURNAL (2008)
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
Christophe Ginestier et al.
CELL STEM CELL (2007)
Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma
L. Tang et al.
GENE THERAPY (2007)
Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma
Takeshi Matsubara et al.
JOURNAL OF SURGICAL ONCOLOGY (2007)
Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer
S. Vitale et al.
GUT (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer
F. Andre et al.
ANNALS OF ONCOLOGY (2006)
alpha B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
JV Moyano et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay
L Perreard et al.
BREAST CANCER RESEARCH (2006)
Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells
H Xin et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics
M Lacroix et al.
ENDOCRINE-RELATED CANCER (2004)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells
SA Shulby et al.
CANCER RESEARCH (2004)
Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1
J Guo et al.
IMMUNOLOGY LETTERS (2003)
Tumor necrosis factor-α-converting enzyme mediates the inducible cleavage of fractalkine
CL Tsou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
